J Korean Med Assoc.  2016 Sep;59(9):713-718. 10.5124/jkma.2016.59.9.713.

The pathogenesis of dry eye disease and trends in treatment

• Hwang H

• KMID: 2391988
• DOI: http://doi.org/10.5124/jkma.2016.59.9.713

Abstract

Dry eye disease (also known as keratoconjunctivitis sicca) is a multifactorial disease of the tear film and ocular surface. It results in various symptoms of discomfort such as pain, tearing, fatigue, and headache. Visual function can also deteriorate, and quality of life is negatively affected. Tear film instability which may lead to damage to the ocular surface with an inflammatory reaction is key to the pathogenesis of dry eye disease. This review discussed the classification, pathogenesis, diagnostic approaches, and treatment options of dry eye disease.

Keyword

Dry eye disease; Tear film instability; Ocular surface; Inflammatory reaction

MeSH Terms

Dry Eye Syndromes
Fatigue
Headache
Inflammation
Keratoconjunctivitis Sicca
Quality of Life
Tears

Figure

• 

  Figure 1 Tear test strips in Schirmer test.

• 

  Figure 2 Evaluation of tear film break up time under cobalt blue light using slit lamp.

Reference

1. Management and therapy of dry eye disease: report of the Management and Therapy Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf. 2007; 5:163–178.

2. Rolando M, Iester M, Macri A, Calabria G. Low spatial-contrast sensitivity in dry eyes. Cornea. 1998; 17:376–379.

3. Denoyer A, Rabut G, Baudouin C. Tear film aberration dyna-mics and vision-related quality of life in patients with dry eye disease. Ophthalmology. 2012; 119:1811–1818.

4. Mertzanis P, Abetz L, Rajagopalan K, Espindle D, Chalmers R, Snyder C, Caffery B, Edrington T, Simpson T, Nelson JD, Begley C. The relative burden of dry eye in patients' lives: com-parisons to a U.S. normative sample. Invest Ophthalmol Vis Sci. 2005; 46:46–50.

5. Abetz L, Rajagopalan K, Mertzanis P, Begley C, Barnes R, Chalmers R. Impact of Dry Eye on Everyday Life (IDEEL) Study Group. Development and validation of the impact of dry eye on everyday life (IDEEL) questionnaire, a patient-reported outcomes (PRO) measure for the assessment of the burden of dry eye on patients. Health Qual Life Outcomes. 2011; 9:111.

6. Baudouin C, Creuzot-Garcher C, Hoang-Xuan T, Rigeade MC, Brouquet Y, Bassols A, Guillemin I, Benmedjahed K, Arnould B. Severe impairment of health-related quality of life in patients suffering from ocular surface diseases. J Fr Ophtalmol. 2008; 31:369–378.

7. Bron AJ, Tomlinson A, Foulks GN, Pepose JS, Baudouin C, Geerling G, Nichols KK, Lemp MA. Rethinking dry eye disease: a perspective on clinical implications. Ocul Surf. 2014; 12:2 Suppl. S1–S31.

8. The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the Inter-national Dry Eye WorkShop (2007). Ocul Surf. 2007; 5:75–92.

9. Akpek EK, Lindsley KB, Adyanthaya RS, Swamy R, Baer AN, McDonnell PJ. Treatment of Sjogren's syndrome-associated dry eye an evidence-based review. Ophthalmology. 2011; 118:1242–1252.

10. Kastelan S, Tomic M, Salopek-Rabatic J, Novak B. Diagnostic procedures and management of dry eye. Biomed Res Int. 2013; 2013:309723.

11. Ahn JM, Lee SH, Rim TH, Park RJ, Yang HS, Kim TI, Yoon KC, Seo KY. Epidemiologic Survey Committee of the Korean Ophthalmological Society. Prevalence of and risk factors asso-ciated with dry eye: the Korea National Health and Nutrition Examination Survey 2010-2011. Am J Ophthalmol. 2014; 158:1205–1214.e7.

12. Norn MS. Desiccation of the precorneal film. I. Corneal wet-ting-time. Acta Ophthalmol (Copenh). 1969; 47:865–880.

13. Paugh JR, Kwan J, Christensen M, Nguyen AL, Senchyna M, Meadows D. Development of a Meibomian Gland Dys-function-Specific Symptom Questionnaire. Eye Contact Lens. 2016; 07. 27. [Epub]. DOI: 10.1097/ICL.0000000000000294.

14. Barabino S, Labetoulle M, Rolando M, Messmer EM. Under-standing Symptoms and Quality of Life in Patients With Dry Eye Syndrome. Ocul Surf. 2016; 14:365–376.

15. Herrero-Vanrell R, Peral A. International Dry Eye Workshop (DEWS): update of the disease. Arch Soc Esp Oftalmol. 2007; 82:733–734.

16. Luo L, Li DQ, Doshi A, Farley W, Corrales RM, Pflugfelder SC. Experimental dry eye stimulates production of inflammatory cytokines and MMP-9 and activates MAPK signaling pathways on the ocular surface. Invest Ophthalmol Vis Sci. 2004; 45:4293–4301.

17. Avunduk AM, Avunduk MC, Varnell ED, Kaufman HE. The comparison of efficacies of topical corticosteroids and nonsteroidal anti-inflammatory drops on dry eye patients: a clinical and immunocytochemical study. Am J Ophthalmol. 2003; 136:593–602.

18. Kunert KS, Tisdale AS, Gipson IK. Goblet cell numbers and epithelial proliferation in the conjunctiva of patients with dry eye syndrome treated with cyclosporine. Arch Ophthalmol. 2002; 120:330–337.

19. Prabhasawat P, Tesavibul N, Mahawong W. A randomized double-masked study of 0.05% cyclosporine ophthalmic emul-sion in the treatment of meibomian gland dysfunction. Cornea. 2012; 31:1386–1393.

20. Tauber J, Davitt WF, Bokosky JE, Nichols KK, Yerxa BR, Schaberg AE, LaVange LM, Mills-Wilson MC, Kellerman DJ. Double-masked, placebo-controlled safety and efficacy trial of diquafosol tetrasodium (INS365) ophthalmic solution for the treatment of dry eye. Cornea. 2004; 23:784–792.

21. Matsumoto Y, Ohashi Y, Watanabe H, Tsubota K. Diquafosol Ophthalmic Solution Phase 2 Study Group. Efficacy and safety of diquafosol ophthalmic solution in patients with dry eye syndrome: a Japanese phase 2 clinical trial. Ophthalmology. 2012; 119:1954–1960.

22. Takamura E, Tsubota K, Watanabe H, Ohashi Y. Diquafosol Ophthalmic Solution Phase 3 Study Group. A randomised, double-masked comparison study of diquafosol versus sodium hyaluronate ophthalmic solutions in dry eye patients. Br J Ophthalmol. 2012; 96:1310–1315.

23. Kojima T, Dogru M, Ibrahim OM, Nagata T, Higa K, Shimizu T, Shirasawa T, Satake Y, Shimazaki S, Shimazaki J, Tsubota K. The effects of 3% diquafosol sodium application on the tear functions and ocular surface of the Cu,Zn-superoxide dis-mutase-1 (Sod1)-knockout mice. Mol Vis. 2014; 20:929–938.

24. Terakado K, Yogo T, Kohara Y, Soeta S, Nezu Y, Harada Y, Hara Y, Amasaki H, Tagawa M. Conjunctival expression of the P2Y2 receptor and the effects of 3% diquafosol ophthalmic solution in dogs. Vet J. 2014; 202:48–52.

25. Yamaguchi M, Nishijima T, Shimazaki J, Takamura E, Yokoi N, Watanabe H, Ohashi Y. Clinical usefulness of diquafosol for real-world dry eye patients: a prospective, open-label, non-interventional, observational study. Adv Ther. 2014; 31:1169–1181.

26. Frucht-Pery J, Chayet AS, Feldman ST, Lin S, Brown SI. The effect of doxycycline on ocular rosacea. Am J Ophthalmol. 1989; 107:434–435.

27. Maatta M, Kari O, Tervahartiala T, Peltonen S, Kari M, Saari M, Sorsa T. Tear fluid levels of MMP-8 are elevated in ocular rosacea: treatment effect of oral doxycycline. Graefes Arch Clin Exp Ophthalmol. 2006; 244:957–962.

28. Dougherty JM, McCulley JP, Silvany RE, Meyer DR. The role of tetracycline in chronic blepharitis: inhibition of lipase production in staphylococci. Invest Ophthalmol Vis Sci. 1991; 32:2970–2975.

29. Shine WE, McCulley JP, Pandya AG. Minocycline effect on meibomian gland lipids in meibomianitis patients. Exp Eye Res. 2003; 76:417–420.